Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study

Inclusion Criteria:

- ≥ 18 years of age

- Biopsy-proven, previously untreated squamous cell carcinoma, adenosquamous carcinoma,
or adenocarcinoma of the uterine cervix

- Clinically visible lesion at least FIGO stage Ib or AJCC 7th edition T1b

- Scheduled to undergo standard of care PET/CT for baseline assessment of disease

- Anticipated to be eligible for curative intent therapy (surgery of chemoradiation
therapy) as determined by the patient's primary oncologist

- If female of child-bearing potential, negative serum or urine pregnancy test ≤ 7 dats
prior to first PET/MRI

- Informed consent reviewed and signed

Exclusion Criteria:

- History of sever reaction to contrast-enhanced CT scan

- Inability to tolerate MRI (e.g., inability to lie flat > 1 hour)

- Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear
implant or metal near eyes

- Poorly controlled diabetes mellitus

- Creatinine > 1.4 mg/dL or GFR < 30 mL/min

- Body Mass Index (BMI) > 35

- Active vaginal bleeding requiring packing and emergent radiation therapy

- Pregnant or lactating female

- History of a prior malignancy within past 5 years, unless disease free for ≥ 3 years

- Substance abuse, medical, psychological, or social conditions that may interfere with
study participation